IL6R and ovarian carcinoma: In a recent phase I clinical trial using the anti-IL-6R mAb tocilizumab in combination with carboplatin/doxorubicin conducted in patients with recurrent epithelial ovarian cancer, T cells of IL-6R mAb-treated patients exhibited features of enhanced activation and secreted high amounts of effector cytokines (171).